Vimarsana
Biggest News Aggregation in the World

Page 3 - Poster Presentations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Poster Presentations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Poster Presentations Today - Breaking & Trending Today

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 - Vimarsana News

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy o

Source: yahoo.com
BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference - Vimarsana News

BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference

November 1, 2023 News Release BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, that it will present two poster presentations at the upcoming American Society of Nephrology (ASN) Kidney Week 2023. Both poster presenta

Source: yahoo.com
Argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions - Vimarsana News

Argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression in generalized myasthenia...

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions - Vimarsana News

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including mini...

Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023 - Vimarsana News

Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...